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C. Renal nitric oxide production in rat pregnancy: role of constitutive nitric
oxide synthases. Am J Physiol Renal Physiol 299: F830–F836, 2010. First
published July 14, 2010; doi:10.1152/ajprenal.00300.2010.—Functional
studies show that increased renal nitric oxide (NO) mediates the renal
vasodilation and increased glomerular filtration rate that occur during
normal pregnancy. We investigated whether changes in the constitu-
tive NO synthases (NOS), endothelial (eNOS) and neuronal (nNOS),
were associated with the increased renal NO production in normal
midterm pregnancy in the rat. In kidneys from midterm pregnant (MP:
11–13 days gestation), late-term pregnant (LP: 18–20 days gestation),
and similarly aged virgin (V) rats, transcript and protein abundance
for eNOS and the nNOS and nNOS splice variants, as well as the
rate of L-arginine-to-L-citrulline conversion, were determined as a
measure of NOS activity. At MP, renal cortical abundance of the total
eNOS protein and phosphorylated (Ser1177) eNOS was reduced, and
L-arginine-to-L-citrulline conversion in the cortical membrane fraction
was decreased; these declines were also seen in LP. There were no
changes in the eNOS transcript. In contrast, L-arginine-to-L-citrulline
conversion in the soluble fraction of renal cortex increased at MP and
then declined at LP. This MP increase was ablated by S-methylthio-
citrulline, a nNOS inhibitor. Using Western blotting, we did not detect
a change in the protein abundance or transcript of the 160-kDa
nNOS, but protein abundance and transcript of the nNOS were
increased at MP in cortex. Collectively, these studies suggest that the
soluble nNOS is responsible for the increased renal cortical NO
production during pregnancy.
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A MARKED RENAL VASODILATION occurs during pregnancy and
leads to increases in renal plasma flow (RPF) and glomerular
filtration rate (GFR) (5, 11, 13). In rats, this increase in RPF
and GFR is maximal by midterm and involves a parallel
relaxation of afferent and efferent arterioles (5, 11). Functional
studies suggest that nitric oxide (NO) mediates the renal
vasodilation, since nonselective NO synthase (NOS) inhibitors
prevent the gestational rise in GFR (6, 9, 12, 14, 25).
Although NO appears to modulate the renal hemodynamic
response during pregnancy, attempts to define the exact origin
of the increased NO remain inconclusive. The use of isoform-
“selective” NOS inhibitors has implicated neuronal and induc-
ible NOS (nNOS and iNOS) (1, 3), while lack of endothelial
NOS (eNOS)-selective inhibitors has prevented direct investi-
gation of eNOS. Alexander et al. (4) reported an increase in
nNOS protein abundance in rats at midterm, which coincides
with maximal renal vasodilation (5), while an unexpected
decline in eNOS protein abundance was also observed. In
contrast, Novak et al. (27) reported no change in renal eNOS
and nNOS protein abundance with pregnancy. Apart from the
unresolved question of NOS protein abundance, large changes
in NOS activity are possible without alterations in protein
abundance. For example, phosphorylation of eNOS at Ser1177
can lead to a 15- to 20-fold increase in NOS activity compared
with unphosphorylated eNOS (18).
To better our understanding of the renal NO system in
pregnancy, we have conducted a series of studies assessing
renal constitutive NOS isoform mRNA abundance, protein
abundance, and activity in kidneys of virgin and pregnant rats.
MATERIALS AND METHODS
Animals. Studies were performed on female Sprague-Dawley rats
(n  51; Harlan Sprague Dawley, Indianapolis, IN) aged 4–5 mo. The
animal studies were reviewed and approved by the West Virginia
University and the University of Florida Animal Care and Use
Committees. All animals were housed separately, provided rat chow
and water ad libitum, and maintained on a 12:12-h light-dark cycle.
Female rats were temporarily housed with males for 1–5 days. Mating
was confirmed by the presence of sperm in the vagina (taken as day
1 of pregnancy) and a continual diestrus vaginal smear. Pregnancy
was confirmed by an increased body weight and the presence of live
fetuses “in utero” on the day of death.
In series 1, in vitro NOS activity was evaluated in tissues harvested
from midterm-pregnant (MP: 11–13 days gestation, n  7), late-
pregnant (LP: 18–20 days gestation, n  8), and similarly aged virgin
(V, n  8) rats. In series 2, NOS mRNA and protein analysis was
carried out in tissues harvested from MP (n  5), LP (n  5), and
similarly aged V (n  5) rats. In series 3, NOS mRNA and protein
analysis was carried out in tissues harvested from MP (n  4), LP
(n  4), and V (n  5) rats.
Tissue harvest. Rats were anesthetized with pentobarbital sodium
(0.7 mg/kg ip) or isoflurane. The kidneys were perfused blood-free
with cold PBS, separated into cortex and medulla, flash frozen in
liquid nitrogen, and stored at 80°C.
NOS activity. NOS activity was measured from the conversion of
[3H]L-arginine to [3H]L-citrulline in kidney tissue, as described pre-
viously (32). Briefly, tissues were homogenized and ultracentrifuged.
The supernatant (soluble) and membrane fractions were assayed. The
soluble fraction contains most of the nNOS, while the membrane
fraction contains mostly eNOS. Endogenous arginine was removed
using Dowex, and the total protein content was determined using a
Bradford assay (7). Samples were assayed in the presence of the
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arginase inhibitors valine (10 mM) and proline (10 mM). Data are
expressed as picomoles of [3H]L-arginine converted to [3H]L-citrulline
per milligram of protein per minute, adjusted for background. Back-
ground was determined by the amount of radioactivity obtained from
heat-inactivated samples (60 min at 80°C) and represented 5% of
the 100% standard, thus representing free tritium or noncationic
tritiated species not bound by the Dowex resin. The 100% standards
were prepared without Dowex and represented the total amount of
counts available for conversion. Some samples were run in the
presence of the nNOS-selective inhibitor S-methylthiocitrulline
(SMTC, 1 M).
Western blotting. Samples were homogenized, and proteins were
separated by SDS-PAGE and transferred to a nitrocellulose mem-
brane, as described previously (32). Ponceau S staining confirmed
equivalent protein loads for cortex (200 g of total protein) and
medulla (100 g of total protein). In series 2, membranes were first
probed with rabbit polyclonal phosphorylated (Ser1177) eNOS anti-
body (Cell Signaling Technology, Danvers, MA) in a 1:250 dilution
of 5% BSA in 0.1% Tris-buffered saline  Tween 20 (TBS-T) for 16
h at 4°C and then with anti-rabbit IgG horseradish peroxidase (HRP)-
linked antibody (Cell Signaling Technology) in a 1:2,000 dilution of
5% nonfat milk in 0.1% TBS-T for 1 h at room temperature. Mem-
branes were then stripped and reprobed for eNOS (mouse monoclonal
antibody, Transduction Laboratories, San Jose, CA) at a 1:250 dilu-
tion for 1 h. Next, goat anti-mouse IgG-HRP conjugate (Transduction
Laboratories) at a 1:2,000 dilution was applied, and the membranes
were incubated for 1 h. Duplicate membranes were run and probed for
nNOS with a rabbit polyclonal antibody targeting the NH2 terminus at
a 1:5,000 dilution for 1 h (16) and then with goat anti-rabbit IgG-HRP
(Bio-Rad, Hercules, CA) at a 1:3,000 dilution for 1 h at room
temperature. In series 3, membranes were probed overnight with a
1:250 dilution of COOH-terminal rabbit polyclonal antibody (PA1–
033, Affinity BioReagents, Golden, CO) or for 1 h with a 1:5,000
dilution of the same NH2-terminal rabbit polyclonal antibody used in
series 2 (gift from Dr. Kim Lau) (22) and then for 1 h with a 1:3,000
dilution of secondary goat anti-rabbit IgG-HRP antibody (Bio-Rad).
Bands of interest were visualized using an ECL Western blot detec-
tion kit (Amersham Biosciences, Piscataway, NJ). Densitometric
analysis was performed using Optimas 6.2 imaging analysis software.
Protein abundance is reported as integrated optical density (OD) units.
The integrated OD was factored for Ponceau S staining (total protein
loaded) and for an internal standard run on each membrane.
PCR. RNA was isolated from tissue using TRI Reagent (Sigma, St.
Louis, MO) and treated with DNase I (Ambion, Austin, TX), and 1–2 g
was reversed transcribed (SuperScript II RNase H Reverse Transcrip-
tase, Invitrogen, Bethesda, MD) with random primers (Invitrogen) in a
total volume of 20–40 l. For control RT reactions, the RT enzyme was
omitted, and primers were designed to include intron-exon splice sites.
Primers were designed using GeneTool software (Biotools, Edmonton,
AB, Canada) with annealing temperatures at 54–62°C. All PCR products
were verified by restriction endonuclease digestion. Cyclophilin (CyP)
was used as an internal reference, since CyP abundance remained con-
sistent in V, MP, and LP rats.
For end-point PCR, preliminary experiments were conducted for
each PCR product to ensure that the number of cycles represented the
linear portion of the PCR OD curve. For each primer set [5= acgc-
cgctgtctcttttc 3= (forward) and 5= tgccttctttcaccttc 3= (reverse) for CyP
(M19533), 5= ccggctgccacctgatcctaacttg 3= (forward) and 5= tgcgcaat-
gtgagtccgaaaatgtc 3= (reverse) for eNOS (XM342615), and 5= cggc-
catcacgatattccctcag 3= (forward) and 5= cccgatctccagcagcatgttg 3=
(reverse) for “total” nNOS (NM052799); primer sets for nNOS and
nNOS were previously published (23, 30)], the cDNA from all
samples was amplified simultaneously using aliquots from the same
PCR mixture. PCR was carried out using 1 g of cDNA, 50 ng of
each primer, 250 M deoxyribonucleotide triphosphates, 1 PCR
buffer, and 2 U of Taq DNA polymerase (Sigma) in a 50-l final
volume. After amplification, 20 l of each reaction were electropho-
resed on 1.5% agarose gels. Gels were stained with ethidium bromide,
images were captured, and the signals were reported as arbitrary units
(i.e., OD  band area) using the Kodak 1D image analysis system
(Eastman Kodak, Rochester, NY). PCR signals were normalized to
the CyP signal of the corresponding RT product to provide a semi-
quantitative estimate of gene expression.
For two-step quantitative real-time PCR, Quantitect SYBR Green
PCR reagents (Qiagen, Valencia, CA) were used according to the
manufacturer’s protocol on an iCycler iQ Multi-color Real-Time PCR
Detection System (Bio-Rad). nNOS primers that would target all
nNOS isoforms [5= aagcctatgccaagaccctgtgtgagatc 3= (forward) and 5=
ccagggcttcgtgctccaggtg 3= (reverse) for total nNOS (NM052799), 5=
cggcgtgctgcgggatca 3= (forward) and 5= tgcggatgcggctcgtcac 3= (re-
verse) for eNOS (XM342615), and 5= gcccttgggtcgcgtctgct 3= (for-
ward) and 5= caccctggcacatgaatcctgga 3= (reverse) for CyP (M19533)]
were designed. Real-time PCR, a more quantitative approach, was not
used to detect nNOS and nNOS mRNA, since multiple bands may
occur with nNOS product amplification (30). Samples were run in
duplicate (2.5–5 l of cDNA per well), and the cycle times from
duplicate wells were averaged. Preliminary experiments were con-
ducted to optimize PCR conditions, ensure the absence of dimer
formation, and affirm that a single PCR product was formed for each
primer pair. For the relative quantification of gene expression, the
comparative threshold cycle (Ct) method was employed (24). Valida-
tion methods were conducted over a 10-fold range of cDNA and over
a 2-fold range of primer concentrations from control and experimental
kidneys to confirm equal efficiency of NOS and CyP. The averaged
NOS Ct was subtracted from the corresponding averaged CyP Ct for
each sample, resulting in 	Ct. The fold change was established by
calculating 2		Ct for experimental vs. control samples (16).
Statistical analysis. One-way ANOVA and Bonferroni’s multiple
comparison test were used to compare mRNA and protein abundance
differences of V, MP, and LP samples. Values are means 
 SE.
Significance was accepted at P  0.05.
RESULTS
As shown in Fig. 1, the abundance of total eNOS (Fig. 1A)
and phosphorylated eNOS (Fig. 1B) falls during pregnancy in
renal cortex. In renal medulla, there were no significant
changes in eNOS or phosphorylated eNOS abundance (Fig. 1,
C and D). Representative blots for renal medulla in Fig. 1, E
and F, show that the eNOS antibody recognized the eNOS- and
phosphorylated eNOS-positive controls (lanes 1 and 2 in Fig.
1E), while the phosphorylated (Ser1177) eNOS antibody recog-
nized only the phosphorylated eNOS-positive control (lane 1 in
Fig. 1F). To measure eNOS transcript, we used CyP mRNA
abundance as an internal control for end-point and real-time
PCR, since CyP mRNA abundance did not change with preg-
nancy (Table 1). Cortical and medullary eNOS mRNA abun-
dance was unaffected by pregnancy, as shown by end-point
and real-time PCR and two different primer pairs (Table 1).
We measured the total [3H]L-arginine-to-[3H]L-citrulline
conversion, as a measure of NOS activity, in renal cortex and
medulla membrane fractions (Fig. 2). [3H]L-arginine-to-[3H]L-
citrulline conversion was significantly lower in LP than V rats
in cortex. In medulla, membrane NOS activity fell in preg-
nancy. There was, however, a significant increase in [3H]L-
arginine-to-[3H]L-citrulline conversion in the soluble fraction
of renal cortex of MP compared with V and LP rats (Fig. 3). In
MP rats, the nNOS-selective NOS inhibitor SMTC reduced the
cortical soluble [3H]L-arginine-to-[3H]L-citrulline conversion
to V values. In medulla, there was no difference in total NOS
activity in the soluble fraction during pregnancy, and SMTC
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inhibited 50% of [3H]L-arginine-to-[3H]L-citrulline conver-
sion in V, MP, and LP rats.
We also measured cortical and medullary nNOS protein
abundance. As shown in Fig. 4, A and B, there was no change
in nNOS protein abundance with pregnancy in animals in
series 3 or in animals in series 2 (data not shown). In contrast,
there was a marked rise in the cortical nNOS protein abun-
dance at MP (Fig. 4C) that occurred in parallel with the
increase in NOS activity in the soluble fraction of cortex (Fig.
3). Representative blots for the nNOS and nNOS proteins
Fig. 1. Relative abundance of kidney endo-
thelial nitric oxide synthase (eNOS) and
phosphorylated (Ser1177) eNOS (P-eNOS) in
cortex and medulla of virgin, midterm preg-
nant (Mid Preg), and late-term pregnant
(Late Preg) rats. A–D: average densitometric
values [integrated optical density (IOD)/in-
ternal standard (Int Std)/Ponceau S (Ponc)]
for eNOS and P-eNOS in renal cortex and
medulla. *Significantly different from virgin
(P  0.05). E and F: representative Western
blots for eNOS and P-eNOS in renal me-
dulla. A molecular weight marker (in kDa) is
shown at far left. Lane 1, P-eNOS-positive
control (lysate of VEGF-treated rat aortic
endothelial cells); lane 2, eNOS-positive
control (lysate of confluent unstimulated rat
aortic endothelial cells); lanes 3 and 4, vir-
gin; lanes 5 and 6, midterm pregnant; lanes
7–9, late-term pregnant.
Table 1. mRNA abundance: series 2 experiments
Renal Cortex Renal Medulla
V MP LP V MP LP
Real-time PCR
eNOS* 0.88 0.85 0.86 0.68
nNOS* 1.04 1.10 0.84 0.78
CyP† 19.28 
 0.15 19.38 
 0.38 17.59 
 0.45 17.92 
 0.06 17.68 




 0.04 0.43 
 0.07 0.36 
 0.04 0.87 
 0.19 0.87 
 0.15 0.73 
 0.04
nNOS 0.71 
 0.15 0.71 
 0.14 0.69 
 0.14 0.78 
 0.06 0.76 
 0.02 0.70 
 0.04
CyP 2.72 
 0.38 2.80 
 0.58 2.54 
 0.47 2.19 
 0.18 2.37 
 0.13 2.33 
 0.10
V, virgin; MP, midterm pregnant; LP, late-term pregnant; eNOS and nNOS, endothelial and neuronal nitric oxide synthase; CyP, cyclophilin. *eNOS and
nNOS real-time PCR values are expressed as mean fold change in gene expression (2		Ct, where Ct is cycle time) compared with V. †CyP real-time PCR values
(means 
 SE) are expressed in Ct. ‡End-point PCR values (means 
 SE) are expressed in arbitrary units; eNOS and nNOS were normalized to CyP.
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(from animals in series 3) are shown in Fig. 5. The total nNOS
transcript was unchanged by real-time and end-point PCR
(Table 1), and there was no change in nNOS mRNA in cortex
or medulla during pregnancy, while nNOS transcript in-
creased in cortex and medulla in MP rats (Fig. 6).
DISCUSSION
The main findings in the present study are that, in renal
cortex of the MP rat, membrane NOS activity and total and
phosphorylated (Ser1177) eNOS protein are not increased when
the gestational renal vasodilation is at a maximum. In contrast,
a marked rise in renal cortical NOS activity in the soluble
fraction is evident, which can be ablated with SMTC, a
nNOS-selective inhibitor (17, 26). Using an antibody to the
NH2 terminus of the 160-kDa nNOS, we saw no change in
protein expression during pregnancy, and the nNOS tran-
script was also unchanged. Transcript and protein abundance
of the functional splice variant nNOS was significantly ele-
vated in renal cortex at MP, coincident with the gestational
renal vasodilation.
Our findings confirm earlier observations that increased
eNOS expression does not contribute to the NO-dependent
renal vasodilation and hyperfiltration that occurs during preg-
nancy. Previous studies indicate no change (27) or a decrease
(4) in eNOS during pregnancy. Here, we report decreases in
total cortical eNOS abundance at MP and LP, and we found no
change in eNOS transcript abundance. Of course, protein
abundance is not the only determinant of eNOS activity, since
there are many possible posttranslational modifications that
affect activity, including phosphorylation of eNOS at Ser1177,
which increases activity by 15- to 20-fold (18). However, we
found that the abundance of phosphorylated eNOS also falls in
renal cortex during pregnancy. Since two different antibodies
detected falls in eNOS and phosphorylated eNOS abundance in
pregnancy, we conclude that decreased eNOS protein probably
accounts for the decrease in renal cortical membrane NOS
activity also seen in this study. Thus, surprisingly, the NO-
dependent renal vasodilation of pregnancy in the rat is not due
to the eNOS.
In contrast to the membrane fraction, we observed a signif-
icant increase in renal cortical soluble NOS activity at MP and
a return in LP that parallels the time course of the gestational
renal vasodilation in the rat (5, 11). iNOS and some nNOS
reside in the soluble fraction. We used a relatively selective
nNOS inhibitor (SMTC, Ki  1.2 nM), which have been
reported to exhibit 100-fold selectivity for rat nNOS com-
pared with iNOS, 10-fold selectivity for nNOS over eNOS in
purified enzyme preparations, and 17-fold selectivity for nNOS
over eNOS in tissues (17, 26). We found that SMTC com-
pletely prevented the rise in soluble NOS activity in renal
cortex in MP while having no impact on V or LP tissue
homogenates. This suggests that the increased soluble NOS
activity originated from a nNOS source. These findings are in
agreement with studies by Abram and colleagues (1), who
reported that acute infusion of another nNOS-selective inhib-
itor, 7-nitroindazole, decreased RPF and GFR in conscious
pregnant rats without affecting renal hemodynamics of virgins.
Although SMTC and 7-nitroindazole are chemically unrelated,
both are used as selective nNOS inhibitors (17). As a caution-
ary note, however, assumptions based on supposedly “isoform-
selective” NOS inhibitors are fraught with problems. Alderton
Fig. 3. Rate of conversion of [3H]L-arginine to [3H]L-citrulline as a measure of
NOS activity in soluble fraction of renal cortex and medulla. Solid columns,
baseline state; hatched columns, S-methylthiocitrulline. *Significantly differ-
ent from V and LP (P  0.05). #Significantly different from baseline (P 
0.05).
Fig. 2. Rate of conversion of [3H]L-arginine to [3H]L-citrulline as a measure of
NOS activity in membrane fraction of renal cortex and medulla of virgin (V),
midterm pregnant (MP), and late-term pregnant (LP) rats. *Significantly
different from V (P  0.05).
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et al. (2) report that much of the confusion results from the
differing criteria used to define selectivity. In fact, when
selectivity is defined on the basis of potency under identical
conditions and in the physiological range, few selective NOS
inhibitors are highly selective. This may explain why nNOS-
selective (1) and iNOS-selective (3) inhibitors have been
shown to ablate the gestational rise in GFR. In view of this, we
cannot rely on selective NOS inhibitors as a means of defining
which NOS isoform(s) play(s) a role in renal hemodynamic
changes that occur with pregnancy; therefore, we also looked
at NOS protein and transcript abundance.
Novak et al. (27) reported no change in medullary nNOS
protein abundance and could not detect the nNOS protein in
renal cortex in V or MP; they observed no change in the
cortical nNOS transcript in MP vs. V. In contrast, Alexander et
al. (4) reported a significant increase in whole kidney nNOS
protein abundance that reached a peak at midterm (13 days
gestation) and remained high throughout the rest of pregnancy.
These workers used a commercially available antibody to the
COOH terminus of nNOS, which we now recognize will detect
all the nNOS splice variants that are present. In the present
study, using an antibody to nNOS (which recognizes only the
unique NH2 terminus of nNOS), we found no change in
protein abundance at MP, and this was confirmed at the
transcript level.
We recently reported that there are nNOS splice variants in
the normal rat kidney and that the proportions of these can
change under pathological conditions (30). Of particular rele-
vance to the present study, one of these splice variants,
nNOS, is a functional enzyme that is entirely cytosolic in
Fig. 4. A and B: relative neuronal NOS
(nNOS)- (nNOS) protein abundance in se-
ries 3 rats (i.e., NH2-terminal antibody) in
cortex and medulla in V, MP, and LP rats. C
and D: relative nNOS abundance in cortex
and medulla. nNOS-positive control is rat cer-
ebellar lysate. Significantly different from V
(P  0.05).
Fig. 5. Top: representative whole membrane
Western blots of renal cortex (300 g of
total protein) and medulla (100 g of total
protein). An NH2-terminal antibody (22)
was used for nNOS (160 kDa, arrow-
head) detection (A), and a COOH-terminal
antibody (PA1–033, Affinity Bioreagents)
was used for nNOS (140 kDa, arrow)
detection (B). Bottom: Ponceau S staining of
corresponding lanes confirming similar pro-
tein loads.
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location (2). Lacking the unique PDZ-binding domain at the
NH2 terminus, nNOS would be recognized by antibodies
targeting the COOH, but not the NH2, terminus. We therefore
conducted a preliminary study assessing the variable 5=-un-
translated regions (5=-UTRs; exon 1a, 1b, and 1c) reported by
Lee and colleagues (23) in the rat kidney. Using RT-PCR and
exon 1a-exon 6 primer pairing, we detected two bands, indi-
cating that nNOS and nNOS transcripts had a common
5=-UTR (30), as previously reported by Huber et al. (19) in the
rat small intestine. Although we report no change in nNOS
transcript abundance with exon 1a-exon 2 primer pairing and a
significant increase in nNOS transcript abundance at MP with
exon 1a-exon 6 primer pairing, we recognize that there may be
additional transcripts for nNOS and nNOS. Indeed, in rat
kidney, Lee et al. (23) identified three nNOS transcripts with
distinct 5=-UTR first exons (exon 1a, 1b, and 1c), all of which
spliced to exon 2 (nNOS). Oberbaumer et al. (28) identified
five nNOS mRNA variants: four encoded for nNOS (exon 2),
and one encoded for nNOS (exon 3). Although these nNOS
mRNA variants may be generated by alternative promoters
encoding the same nNOS protein, it is possible that the various
nNOS transcripts with different 5=-UTRs may have different
functional properties that may influence mRNA translational
efficiency, alter mRNA localization, or alter mRNA stability.
This may account for the differences in cortical and medullary
nNOS and nNOS transcript expression compared with
nNOS and nNOS protein abundance seen in the present
study.
We used the previously characterized COOH-terminal
nNOS antibody (30) to directly test whether nNOS might
contribute to the gestational renal vasodilation and observed a
marked increase in the protein abundance. Unlike the nNOS,
nNOS contains a unique NH2 terminus of 6 amino acids and
lacks the first 236 amino acids of nNOS, which contains the
PSD-95 disks large/ZO-1 homology (PDZ) and protein inhib-
itor of NOS (PIN) domains. The PDZ domain of nNOS
mediates interaction with postsynaptic density protein 95
(PSD-95) of neurons and 1-syntrophin (part of the dystrophin
complex) of myocytes, which anchors nNOS in the plasma
membrane (8). Without a PDZ domain, nNOS would occur in
the cytosol, as shown by Huber et al. (19) in the rat intestine.
Furthermore, the PIN domain contains a binding site for the
protein inhibitor of NOS (21), and without a PIN domain,
nNOS cannot be regulated by PIN. Therefore, nNOS may
be regulated by other mechanisms, such as alternate promoter
usage and pre-mRNA splicing events (31). With no PDZ and
PIN domains, the secondary and/or tertiary structure of nNOS
may be similar to iNOS, and we speculate that iNOS-selective
inhibitors may inhibit the activity of iNOS and nNOS. Also,
with similar molecular weights, nNOS may comigrate with
iNOS and/or be mistaken for iNOS in the absence of appro-
priate positive controls.
Brenman and colleagues (8) reported that nNOS trans-
fected in COS cells was catalytically active, with a Km for
arginine similar to nNOS, and fully dependent on calcium/
calmodulin. Several in vivo studies using wild-type and
nNOS/ mice also suggested a functional role for nNOS.
For example, in wild-type mice, nNOS is a functional enzyme
accounting for much of the citrulline formation in many brain
areas (15). The nNOS/ and eNOS/ double-knockout
mice exhibit normal penile erection mediated by nNOS (20).
In nNOS/ mice, nNOS abundance increases, suggesting a
compensatory upregulation of nNOS when nNOS-derived
NO is deficient (15). In humans, nNOS has been localized in
the spinal cord and is upregulated in astrocytes of the ventral
horn and white matter in patients with amyotrophic lateral
sclerosis (10). This suggests that nNOS may be upregulated
in disease states, as also reported by us in the rat kidney with
chronic kidney disease (30). The present study suggests that
renal cortex nNOS is upregulated in response to physiological
stimuli in normal pregnancy, which we suggest may play an
important role in the renal vasodilation at MP.
In summary, the increase in renal cortical NO generation
during pregnancy cannot be attributed to increased abundance
Fig. 6. Relative nNOS and nNOS mRNA
abundance in renal cortex (A and C) and me-
dulla (B and D) assessed by end-point PCR.
There was no significant difference in cortical
or medullary nNOS mRNA abundance be-
tween V, MP, and LP. However, nNOS
mRNA abundance was significantly increased
in MP rats compared with V and LP rats. AU,
arbitrary units [i.e., optical density (OD) 
area/cyclophilin (CyP)]. *Significantly differ-
ent from V and LP (P  0.05).
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or activity of eNOS. Rather, nNOS in the soluble fraction of
renal cortex provides the likely source. Future studies should
investigate the specific location and the signaling pathway
responsible for activating the renal cortical nNOS in normal
pregnancy.
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